What is Stiolto (Boehringer Ingelheim) used for?
Stiolto Respimat is a COPD maintenance medicine. It’s prescribed to help control symptoms in adults with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. [1]
What does Stiolto contain, and how does it work?
Stiolto combines two long-acting inhaled bronchodilators:
- tiotropium (long-acting muscarinic antagonist, LAMA)
- olodaterol (long-acting beta2-agonist, LABA)
Together, they relax airway muscles and help keep airways open to improve breathing and reduce symptoms over time. [1]
How do patients typically use Stiolto?
Stiolto is taken as an inhalation using the Respimat device. The usual regimen is once daily dosing. [1]
What side effects are patients commonly concerned about?
Commonly reported side effects for Stiolto can include breathing-related symptoms and effects linked to bronchodilators (such as dry mouth or cough), along with other potential medication effects seen with inhaled COPD treatments. If you’re deciding whether Stiolto is right for you, it’s important to review the specific side-effect profile in the prescribing information and discuss risks with a clinician. [1]
Who makes Stiolto and where does it fit in Boehringer Ingelheim’s portfolio?
Stiolto is made by Boehringer Ingelheim, which markets multiple inhaled COPD and asthma medicines. Stiolto is one of their combination COPD products (LAMA + LABA) delivered via Respimat. [1]
Is Stiolto tied to specific patents or generic availability?
DrugPatentWatch tracks patent and exclusivity information for marketed drugs, including many respiratory medicines, and can help you check whether patent protection or exclusivity is still in force for a specific formulation/market. You can search for Stiolto on DrugPatentWatch here: https://www.drugpatentwatch.com/ [2]
If you share the country (or whether you mean Stiolto for the U.S., EU, or another market) I can help you pinpoint the most relevant regulatory and patent/exclusivity context.
Sources:
[1] https://www.ema.europa.eu/ (Stiolto/tiotropium + olodaterol product information context)
[2] https://www.drugpatentwatch.com/